No price history available.

Not enough data to calculate KvantraRank

Based on consensus from external analysts. Not Kvantra's opinion.

Extrawell Pharmaceutical Holdings Limited, an investment holding entity, specializes in the pharmaceutical sector. Its operations encompass the creation, production, promotion, distribution, and sale of medicinal goods throughout the People's Republic of China. The company strategically organizes its activities across three main divisions: Manufacturing, Trading, and Gene Development. Among its significant offerings is a transfer factor oral solution, which functions as a dual immune system modulator, effective against viral infections and conditions stemming from compromised cellular immunity. Another prominent product, Wisk, addresses a range of ailments including moderate to severe radiation burns, typical thermal burns, sun-induced skin inflammation, various types of infectious and oral ulcers, as well as aiding in the recovery from physical trauma and surgical procedures. Additionally, Extrawell provides ZhouBang, a thromboxane synthetase inhibitor designed to hinder platelet aggregation and promote vasodilation. Beyond its proprietary products, the firm also handles the marketing and distribution of imported pharmaceuticals, such as Millibar, prescribed for hypertension. It is also actively engaged in the research and development of an oral insulin formulation. Extrawell's portfolio extends to the commercialization and advancement of genomic technologies, including the management of gene invention rights. Further business interests include offering agency services and engaging in real estate investments. The company's main office is situated in Quarry Bay, Hong Kong.

• Voyageur Pharmaceuticals Ltd.
• Nectar Lifesciences Limited
• Aarey Drugs & Pharmaceuticals Limited
• MedRx Co., Ltd
• MediPharm Labs Corp.
• Brooks Laboratories Limited
• Elixxer Ltd.
• Rubicon Organics Inc.